Strides Pharma Science Ltd - 532531 - Business Responsibility and Sustainability Reporting (BRSR)
Strides Pharma Science reported 3 voluntary product recalls in FY26 due to quality control issues. This highlights potential operational and regulatory risks related to product quality.
Jul 21 2026 15:30:21
Strides Pharma Science Ltd - 532531 - Company Has Fixed The Record Date For Final Dividend For FY26 As Friday, July 31, 2026
Strides Pharma Science fixed July 31, 2026, as Record Date for its ₹5 final dividend for FY26. The dividend, if approved at the August 14, 2026 AGM, will be paid within 30 days.
Jul 20 2026 13:14:27
Strides Pharma Science Ltd - 532531 - Announcement under Regulation 30 (LODR)-Restructuring
Strides Pharma Science successfully completed the divestment of its majority stake in Pivot Path to a consortium led by Ascent Capital for Rs.100 crore. The company received Rs.75 crore upfront, with the remaining Rs.25 crore due in a year. Pivot Path is now classified as an associate company.
Jul 03 2026 17:59:24
Strides Pharma Science Ltd - 532531 - Announcement under Regulation 30 (LODR)-Restructuring
Strides Pharma Science divested a majority stake in its wholly-owned subsidiary, Pivot Path Private Limited, to a consortium led by Ascent Capital for Rs. 100 crore. The transaction also includes Ascent Capital's primary infusion of Rs. 50 crore into Pivot Path to accelerate its growth. Post-transaction, Pivot Path will be reclassified as an Associate Company.
Jun 27 2026 16:02:09
Strides Pharma Science Ltd - 532531 - Announcement under Regulation 30 (LODR)-Press Release / Media Release
Strides Pharma Science divested a majority stake in its wholly-owned subsidiary, Pivot Path, to a consortium led by Ascent Capital. Strides will realize ₹100 crore while retaining a 20% stake, with Pivot Path valued at ₹230 crore post-money.
Jun 27 2026 16:00:27
Read More